Loading clinical trials...
Loading clinical trials...
Prospective Registry-Based Study Evaluating the Effectiveness and Safety of Odevixibat in Participants With Alagille Syndrome (ALGS)
This study will collect information from patients with Alagille syndrome (ALGS) as they use odevixibat (Bylvay) in their daily lives. Odevixibat is a medicine that helps patients with ALGS, a rare disease that harms their liver and causes itching. The main aim of this study is to observe the long-term, everyday effectiveness and safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Childrens Hospital Los Angeles
Los Angeles, California, United States
UCSF Pediatric Gastroenterology
San Francisco, California, United States
The Children's Mercy Hospital
Kansas City, Missouri, United States
Columbia University
New York, New York, United States
NYU Langone - NYU Grossman School of Medicine
New York, New York, United States
Le Bonheur Children's Hospital
Memphis, Tennessee, United States
UT Southwestern Childrens Medical Center
Dallas, Texas, United States
Proactive El Paso,LLC
El Paso, Texas, United States
Start Date
April 22, 2025
Primary Completion Date
November 1, 2029
Completion Date
November 1, 2029
Last Updated
March 2, 2026
30
ESTIMATED participants
Lead Sponsor
Ipsen
NCT05035030
NCT07293897
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT02963077